Tavneos®.C: Avacopan. I: Tavneos, as an adjunct therapy to standard immunosuppressive treatment based on rituximab or cyclophosphamide with glucocorticoids, is indicated for the treatment of adult patients with severe active ANCA vasculitis (GPA/MPA). Po: Oral intake 30 mg (3 capsules of 10 mg each) twice daily in the morning and evening with food. CI: Hypersensitivity to the active substance or any of the excipients. W/P: Hepatotoxicity; angioedema; monitoring of blood count (white blood cells); severe infections; hepatitis B virus reactivation; cardiac disorders; malignant tumours; macroglycerin hydroxystearate. P/L: Use during pregnancy and in women of childbearing age who are not using a contraceptive method is not recommended. It is not known whether Avacopan is excreted into breast milk. The benefit of breastfeeding to the child should be weighed against the benefit of treatment to the patient. UE: Very common: upper respiratory tract infection, nasopharyngitis; headache; vomiting, diarrhoea, nausea; increased liver test; decreased white blood cell count. Frequent: pneumonia, lower respiratory tract infection, influenza, bronchitis, cellulitis, urinary tract infection, herpes zoster, sinusitis, oral candidiasis, oral herpes, otitis media, rhinitis, gastroenteritis; neutropenia; upper abdominal pain; increase in blood creatine phosphokinase. Occasional: angioedema. IA: Avacopan is a substrate of CYP3A4. Co-administration of inducers or inhibitors of this enzyme may affect the pharmacokinetics of Avacopan. See SmPC. P: Tavneos 10 mg: 30 and 180 hard capsules. List B. Detailed information: www.swissmedicinfo.ch. Date of information: January 2024. Marketing authorization holder: Vifor Fresenius Medical Care Renal Pharma Ltd, St. Gallen. Distribution: Vifor Pharma Switzerland AG, CH-1752 Villars-sur-Glâne | CH-AVA-2300143
This medicinal product is subject to additional monitoring. For further information, see professional information TAVNEOS® on www.swissmedicinfo.ch.
E 01/2024 CH-AVA-2300101 v2.0
Templates for the request of cost reimbursement
TAVNEOS® is indicated as an adjunctive treatment to standard immunosuppressive treatment that includes rituximab or cyclophosphamide with glucocorticoids for the treatment of adult patients with severe, active ANCA-associated vasculitis (GPA/MPA).1
TAVNEOS® is not included in the specialties list (SL/LS).
To simplify the process on your side, we offer templates for the request of cost reimbursement which can be sent to the respective health insurance company or the medical examiner.
Download the TAVNEOS® cost reimbursement request form here
Healthcare professionals may request a full copy of the cited clinical trial report from Vifor Pharma Switzerland.
Al Hussain T, et al. Pathophysiology of ANCA-associated Vasculitis. Adv Anat Pathol 2017;24(4):226–34.
Basu N, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 2014;73(1):207–11.
Bekker P, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One 2016;11(10):e0164646.
Charles P, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Ann Intern Med 2020;173(3):179–87.
Cortazar F, et al. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. Kidney Int Rep 2023;8(4):860–70.
EMA. First-in-class medicine recommended for treatment of rare blood vessel inflammation. Nov. 2021. https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Last access: October 2023.
Hellmich B, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2023;0:1–18.
Hunter RW, et al. ANCA-associated vasculitis. BMJ 2020;369:m1070.
Hutton HL, et al. ANCA-associated vasculitis: pathogenesis, models, and preclinical testing. Semin Nephrol 2017;37(5):418–35.
Jayne D, Bekker. Integrated Safety of Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol 2022;33:794–5 (Abstract SA-PO696).
Jayne D, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med2021;384(7):599–609.
Jayne D, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med2021;384(7):599–609. [Supp Appendix].
Jennette JC, Nachman PH. ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol 2017;12(10):1680–91.
Lamprecht P, et al. Mind the Gap: Balancing Remission and Risk of Relapse in ANCA-Associated Vasculitis. EMJ Rheumatol 2021;8(1):36–42.
Liberman AC, et al. Regulatory and Mechanistic Actions of Glucocorticoids on T and Inflammatory Cells. Front Endocrinol (Lausanne) 2018;9:235.
Little MA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69(6):1036–43.
McDowell P, et al. Quantification of Glucocorticoid-associated morbidity in Severe Asthma using the Glucocorticoid Toxicity Index. J Allergy Clin Immunol Pract 2021;9(1):365–72.
McGregor JG, et al. Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease. Clin J Am Soc Nephrol 2012;7(2):240–7.
Nozaki Y. New insights into novel therapeutic targets in ANCA-associated vasculitis. Front Immunol 2021;12:631055.
Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol 2016;3(3):122–33.
Quartuccio L, et al. Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. J Autoimmun 2020;108:102397.
Robson J, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2015;54(3):471–81.
Specks U, et al. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. N Engl J Med 2013;369(5):417–27.
Stone J, et al. The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum 2022;55:152010.
Stone JH, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med 2010;363(3):221–32.
Strand V, et al. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol 2023;5:e451–60.
TAVNEOS® Fachinformation, www.swissmedicinfo.ch.
Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176(3):1305–10.
Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009;23(3):391–401.
Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ 2020;368:m421.
Walsh M, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 2020;382(7):622–31.
Yates M, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75(9):1583–94.
Scroll down